Understanding The Mechanisms Underlying Airway Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
Changes in the structure of the lung contribute to the development of disease, but are not responsive to our current therapies. I have found two key structural proteins that are altered in asthma. This research will characterise the regulation and role of these proteins in the disease process. In addition, it will determine if these proteins also contribute to the development of other serious fibrotic diseases, for which there are no current treatments.
Epithelial-Mesenchymal Cell Communication; Towards New Therapeutic Targets For Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$794,596.00
Summary
Fibrosis causes disability and death with millions of people affected each year. Current treatments are limited and there is a need to better understand the changes that drive fibrosis. In this study we will investigate how cells communicate to initiate and drive fibrosis. Using readily available drugs we will test new ways to alter cell communication to stop the disease and thus, develop a common and effective therapy that will change the future for people living with fibrosis.
Elucidation Of The Aetiology Of Airway Remodelling In COPD
Funder
National Health and Medical Research Council
Funding Amount
$626,979.00
Summary
This project grant aims to discover how cigarette smoking induces the development of Chronic Obstructive Pulmonary Disease (COPD) by understanding how smoking drives the key pathological charges in the airways, airway remodelling. Our research to-date has found that cells from people with COPD have an hightened response to cigarette smoke and we aim to uncover the molecular basis of this aberrant response.
The Anti-inflammatory Role Of Collagen IV In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$317,076.00
Summary
We have discovered that a protein, tumstatin, is missing from the lungs of people with asthma. We now have exciting data showing, for the first time, that tumstatin can stop inflammation. If tumstatin is part of the system that normally limits inflammation in the lungs its absence in asthma may be critical. In this grant we will discover how tumstatin works to block inflammation and why it is absent in asthma. Our studies will provide vital information about the role of tumstatin in the airways.
Airway Extracellular Matrix And Smooth Muscle In Chronic Obstructive Pulmonary Disease (COPD)
Funder
National Health and Medical Research Council
Funding Amount
$828,849.00
Summary
In asthma the layer of airway smooth muscle is thicker, due to more muscle cells. Airway narrowing is excessive but reversible. In chronic obstructive pulmonary disease (due mainly to smoking) the layer of airway smooth muscle is also thicker but the airways cannot be induced to open, or close. Our data suggest that this fixed airway narrowing is likely to be due to an excess of matrix between cells rather than muscle. This project will comprehensively test this new finding.
Mast Cells - Bystanders Or Instigators Of Airway Remodelling In Asthma?
Funder
National Health and Medical Research Council
Funding Amount
$623,764.00
Summary
Current asthma treatments have little effect on changes to the breathing tubes in our lungs. The tubes are thickened and stiffer, with more muscle, blood vessels, matrix and mucus. We propose that a particular inflammatory cell, called a mast cell, causes these changes to the breathing tubes and we will find out how it does that. Thus this project will establish why and how the changes to the breathing tubes happen in asthma and reveal how best to target and reverse-prevent them in the future.
Peroxisome Proliferator Activated Receptor Gamma Is A Novel Therapeutic Target For Inflammation And Remodelling In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$307,436.00
Summary
Asthma affects over 2 million Australians with 300 deaths each year. Current drugs are not always effective. A new approach is to reduce the thickening and stiffening of the airway muscle found in asthma. Rosiglitazone, an antidiabetic drug in current use, inhibits growth of airway muscle in the test tube and chest tightening in a mouse model of asthma. Cells from asthmatics will be used to confirm these positive findings, and to support rapid clinical evaluation of this drug to benefit patients ....Asthma affects over 2 million Australians with 300 deaths each year. Current drugs are not always effective. A new approach is to reduce the thickening and stiffening of the airway muscle found in asthma. Rosiglitazone, an antidiabetic drug in current use, inhibits growth of airway muscle in the test tube and chest tightening in a mouse model of asthma. Cells from asthmatics will be used to confirm these positive findings, and to support rapid clinical evaluation of this drug to benefit patients.Read moreRead less
The Role Of The Alveolar Macrophage In The Regulation Of Inflammation And Matrix Destruction In COPD
Funder
National Health and Medical Research Council
Funding Amount
$397,420.00
Summary
Chronic obstructive pulmonary disease (COPD) is a major public health problem world-wide. COPD is a common disease and a leading cause of morbidity and mortality. The prevalence, morbidity and mortality of COPD are increasing in many westernized countries. Chronic cigarette smoking is the main cause of COPD, and the demographics of COPD reflect the demographics of cigarette smoking. Globally, 47% of men and 12% of women smoke, but only 15% of smokers will develop COPD. Cells within the lung call ....Chronic obstructive pulmonary disease (COPD) is a major public health problem world-wide. COPD is a common disease and a leading cause of morbidity and mortality. The prevalence, morbidity and mortality of COPD are increasing in many westernized countries. Chronic cigarette smoking is the main cause of COPD, and the demographics of COPD reflect the demographics of cigarette smoking. Globally, 47% of men and 12% of women smoke, but only 15% of smokers will develop COPD. Cells within the lung called alveolar macrophage produce substances called proteins called cytokines and matrix metalloproteinases (MMPs) which may be important in the development of emphysema or COPD. In COPD, these patients have an inflammatory and destructive process in their lungs, which leads to a progressive loss of breathing capacity, and ultimately death. There have been significant improvements in the treatment of asthma over the last 30 years. Effective new drugs such as selective and long-acting bronchodilators, more effective inhaled corticosteroids, and improved delivery systems have been introduced. Arguably inhaled steroids may be the single most important treatment in preventing the symptoms and exacerbations of asthma and although useful in asthma, the benefits of inhaled steroids in COPD has not yet been established, but inhaled steroids are still used in the treatment of COPD despite the paucity of evidence for its usefulness in patients with COPD. This treatment is expensive and may also produce side-effects. We would like to investigate the effect of inhaled steroids on several inflammatory and destructive processes in patients with COPD. These studies will form the basis of a more rational approach in the management of COPD. Improved understanding of the molecular mechanisms that underlie COPD could lead to improved treatments for this disease which is set to be the third most important cause of death in 2010.Read moreRead less